The Marseille Cancer Research Center celebrates its 50th anniversary ! -

Our team brings together multidisciplinary profiles to work on the development of tools that will ensure a better management and treatment of aggressive solid tumors (metastatic breast and colon cancers).

Our scientific priority is to tackle breast and colon metastatic cancers that are aggressive or resistant to treatments. This topic is addressed through four ambitious projects:

  • A better classification of tumors and identification of predictors of resistance or response to treatments (at the bulk and single cell levels),
  • The establishment of relevant pre-clinical models that recapitulate resistance or response to treatment, and can be used as a screening to tool to identify the best therapy for a given tumor,
  • The use of liquid biopsies as a quasi-non-invasive tool to anticipate tumor progression/resistance occurrence,
  • The design of new therapies for tumors aggressive or resistant to other treatments.

General workflow

To give the general direction to these projects, the team is headed by F Bertucci (pioneer in tumor profiling, medical oncologist and head of the translational research committee at the Paoli Calmettes Institute) and E Mamessier (Researcher at INSERM, cellular biologist, immunologist and expert at setting translational studies). This co-leadership allows to combine technical development and breaking new scientific topics with relevant clinical questions and access to patients’ samples.
The completion of each project is feasible thanks to the support of 18 additional people, each gifted in a specific discipline (bioinformatics, immunology, molecular biology, cellular biology, biochemistry…), so that they can work on most problematics, independently of the type of treatment.
In addition, the team is fully equipped with next generation sequencing (Nextseq500), pan-transcriptomic (Affymetrix), array-based comparative genomic hybridization (Agilent), circulating tumor DNA (BioRad) or Circulating tumor cells isolation (Parsortix and micromanipulator) platforms, and microfluidic devices (Ibidi, Fluigent, ..), Live Cell Imaging System, cell culture rooms dedicated to the processing of human samples…
Altogether, we develop precision medicine strategies based upon better classification of tumors, more therapeutic options, better targeting and better comprehension of the mechanisms of resistance to treatments.

Come and join us in this adventure !

All techniques/technologies used in the team are designed to fit with patients’ samples and to meet clinical needs: Profiling and classification of tumors, single cells resolution caomputational approaches, multiplexed-immunofluorescence from FFPE tissues, Patient tumor derived organoids (simple or complex co-cultures), liquid biopsies analysis, identification of new targets and design of new treatments.


  • Resistance to treatment
  • Aggressive cancers
  • Antibody drug conjugates
  • Circulating Tumor cells
  • Tumoral Microenvironment

OncoPredic’Team in June 2023

OncoPredic’Team at the LMDF charity run for patients


Team publications

the Team publications
Feb 2018 Annals of translational medicine

CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F

Mar 2020 Molecular oncology

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.

Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S

Aug 2019 Cancers

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.

de Nonneville A, Finetti P, Adelaide J, Lambaudie É, Viens P, Gonçalves A, Birnbaum D, Mamessier E, Bertucci F

Jun 2019 JCI insight

Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E

Apr 2018 Biochimica et biophysica acta. Reviews on cancer

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.

Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E

Apr 2020 Hepatology (Baltimore, Md.)

Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG

Jun 2019 Cancers

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease.

Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R

Jun 2023 Cancer research

CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.

Fattori S, Le Roy A, Houacine J, Robert L, Abes R, Gorvel L, Granjeaud S, Rouvière MS, Ben Amara A, Boucherit N, Tarpin C, Pakradouni J, Charafe-Jauffret E, Houvenaeghel G, Lambaudie E, Bertucci F, Rochigneux P, Gonçalves A, Foussat A, Chrétien AS, Olive D